Marabella P C, Tritsch G L, Moore R H, Takita H
J Surg Oncol. 1976;8(6):501-5. doi: 10.1002/jso.2930080609.
Fifty-one previously untreated cases of lung carcinoma and 7 normal healthy controls were evaluated with respect to serum ribonuclease (S-RNase) levels. Cellular immunity was tested in 22 of these 51 cases by leukocyte migration inhibition test (MIT) using extract of culture cell line of lung carcinoma. S-RNase levels in lung carcinomas were significantly elevated. There appeared to be no difference in S-RNase levels by histological classification. More striking was high S-RNase level in disseminated versus localized cases. MIT results indicated impairment of cellular immunity in those cases of more elevated S-RNase. S-RNase may be implicated in blocking phenomenon associated with neoplastic disease.
对51例未经治疗的肺癌患者和7名正常健康对照者的血清核糖核酸酶（S-RNase）水平进行了评估。在这51例患者中的22例通过使用肺癌培养细胞系提取物的白细胞迁移抑制试验（MIT）检测了细胞免疫。肺癌患者的S-RNase水平显著升高。按组织学分类，S-RNase水平似乎没有差异。更显著的是，播散性病例与局限性病例相比S-RNase水平较高。MIT结果表明，在那些S-RNase水平较高的病例中细胞免疫受损。S-RNase可能与肿瘤性疾病相关的阻断现象有关。
